Companion Animal Vaccines - development, efficacy and use

Wednesday, 02 November 2005

Companion Animal Vaccines - development, efficacy and use
Wednesday, 02 November 2005 09:00 - 17:00 (GMT)

Birkbeck College
Room B04
Malet Street
United Kingdom

Map and Directions

9:15 – 9:45 Registration – Tea, coffee and biscuits

9:45 - 10:00 Introduction - Prof Michael Day, University of Bristol (Meetings Chair)

10:00 - 10:30 Current issues in companion animal vaccination.
Prof Michael Day, University of Bristol, UK

10:30 – 11:00 From Research to Pets: The challenges for the Industry.
Dr. Samuel Thevasagayam, Pfizer Animal Health

11:00 – 11:20 Morning tea/coffee in the exhibition hall

11:20 – 11:50 The route from an idea to a safe and efficacious vaccine.

Mr Jac Bergman, Intervet UK Ltd

The route form an idea to a safe and efficacious vaccine consists of the following 4 phases:

·            Research phase

·            Development phase

·            Production and batch release.

·            Pharmacovigilance and post registration trials/data

Examples will be given to illustrate the challenges met during these 4 phases.

11:50 – 12:20 Immune senescence - How ageing may influence vaccine efficacy in the cat.

Dr. David Campbell, University of Ulster

Immune senescence refers to the functional decline in immune status which occurs with age. Alterations to the T cell repertoire are characteristic of ageing in all mammalian species and have been well documented. They include a reduction in thymic emigration leading to a decreased naive T cell pool; the accumulation of expanded clones of memory and effector T cells, in response to continuous antigenic challenge; and the accumulation of indolent cells, as the result of replicative senescence. The net result of these changes is a compromised environment for the induction of a primary immune response to novel antigen. Our studies in the cat suggest that age is an important factor in the generation of an adequate vaccine response and alternative vaccination regimes may be required to ensure adequate protection in older animals.

12:20 - 13:30 Lunch in the exhibition hall

13:30 – 14:00 Factors affecting the serological response of companion animals to rabies vaccination.

Dr Anthony Fooks, Veterinary Laboratories Agency, UK

This study will discuss the reasons why some companion animals fail to show a sufficient antibody titre following rabies vaccination. The probability of failure to detect an antibody titre of at least 0.5 IU/ml was measured by logistic regression as a function of various risk factors: choice of vaccine, time interval between vaccination and sampling, sex and age of the animal and its country of origin. Analysis indicated highly significant (P<0.001) effects on the test failure rate for all risk factors with the exception of the sex of dogs, while in cats all factors studied were found to have a significant effect (P<0.05). The number of vaccine doses, and timing of the blood test post-vaccination appear to be the two most important factors in achieving a successful test result. Current studies are further investigating the role of host animal MHC variability in response to vaccination in cats and dogs

14:00 - 14:30 Do dogs vary in their response to Rabies vaccination?

Dr. Lorna Kennedy, University of Manchester, UK

Since the Pet passport scheme was introduced, thousands of dogs have been vaccinated against rabies. There is considerable variation in the response to the vaccination, and 5% of dogs fail to produce sufficient antibody.

We have analysed a dataset with over 10,000 dogs, to assess what factors affect a dog’s response to vaccination. We have considered vaccine batch, breed, gender, age, weight, height and time between vaccination and sampling for antibody titre.  We predict that response may be associated with the MHC type of the dogs.

14:30 – 15.00 Afternoon Tea/Coffee and cakes in the exhibition area

15:00 – 15:30 AIDS vaccine studies in the feline immunodeficiency virus model.

Dr. Stephen Dunham, University of Glasgow, UK

In the face of the continuing AIDS pandemic, the need for an effective vaccine against human immunodeficiency virus remains as great as ever.  Several animal model systems have been used to test a large number of candidate lentiviral vaccines, including macaques, and the feline immunodeficiency virus (FIV) model in cats. The talk will outline the FIV model and some of the major breakthroughs and questions remaining.

15:30 – 16:00 IFN-g, a new marker to evaluate poxvirus-based vaccines for equine respiratory viruses.

Romain Paillot, Animal Health Trust, Centre for Preventive Medicine

Although methods to detect and measure virus-specific antibody responses are well established, the development of reliable assays for the easy measurement of cellular immune responses (particularly virus-specific cytotoxic T lymphocyte responses) has lagged behind vaccine development. This study will describe the development of a method to  synthesising cells in the horse. This newgmeasure virus-specific IFN- marker was compared with EHV-1 specific, CTL activity. It was then applied to evaluate the cell mediated immunity (CMI) induced by vaccination with recombinant canarypox viruses coding for haemagglutinin molecules from equine influenza virus, or a NYVAC-based vaccine coding for a know cytotoxic T lymphocyte (CTL) target protein of EHV-1.

16:00 – 16:30 Development of a therapeutic vaccine for canine malignant melanoma

Dr Brain Catchpole, Royal Veterinary College

16:30 Close



Subscribe to our e-newsletter to get updates of this and other  meetings

First name:
Last name:
Email address:


Contact Details

Payment Instructions

    • Payment can be made by Visa or Mastercard online by secure server or by post
    • Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process) to

    Sally Wheatland
    PO Box 49717
    N20 8WH.

    Payment must be received prior to the meeting

© 2019
Quick, easy and affordable online event registration and event management software for all event sizes.